When was Calidi Biotherapeutics founded?

Calidi Biotherapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Calidi Biotherapeutics located?

Calidi Biotherapeutics is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does Calidi Biotherapeutics have?

As of Jul 31, 2026, the latest employee count at Calidi Biotherapeutics is 32.

Is Calidi Biotherapeutics a funded company?

Calidi Biotherapeutics is a funded company, having raised an undisclosed amount across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 21, 2020.

When was the latest funding round of Calidi Biotherapeutics?

Calidi Biotherapeutics' latest funding was a $***** Post IPO round on Jul 29, 2024, with participation from 0 investor.

Where does Calidi Biotherapeutics rank among its competitors?

Calidi Biotherapeutics ranks 459th amongst 3298 active competitors, of which 1123 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Calidi Biotherapeutics?

Calidi Biotherapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Calidi Biotherapeutics - 2026 Company Profile, Team, Funding & Competitors

Calidi Biotherapeutics is a public company based in San Diego (United States), founded in 2018 by Megan Camaisa. It operates as a Developer of gene therapies for the treatment of cancer and other indications. Calidi Biotherapeutics has raised an undisclosed amount in funding from Wong & Partners. The company has 3298 active competitors, including 1123 funded and 778 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of gene therapies for the treatment of cancer and other indications. It is a clinical-stage immuno-oncology company developing stem cell-based platforms to deliver oncolytic viruses that target solid tumors and enhance immune responses against metastatic cancer.

Website: www.calidibio.com/
Social
Email ID: *****@calidibio.com
Phone Number: +1 **********
Registered Address: San Diego, California

Key Metrics

Founded Year

2018

Location

San Diego, United States

Stage

Public

Latest Funding Round

Post IPO, Jul 29, 2024, $*****

Investors

Wong & Partners & 3 more

Ranked

459^th among 3298 active competitors

Employee Count

32 as on Jul 31, 2026

Similar Companies

BeiGene & 631 more

Exit Details

Public

View Calidi Biotherapeutics' full profile

Calidi Biotherapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CALIDI BIOTHERAPEUTICS CIN: 471437012 , United States, Active	Dec 26, 999	-	23 (As on Dec 31, 2024)	-

Calidi Biotherapeutics got listed on Nov 01, 2021.

Click here to take a look at Calidi Biotherapeutics's IPO in detail

Calidi Biotherapeutics has raised funding over 7 rounds. Its first funding round was on Jan 21, 2020. Calidi Biotherapeutics has 4 institutional investors.

Here is the list of recent funding rounds of Calidi Biotherapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 29, 2024	2335868	Post IPO	1804915	4260080	1037931	7061618
Mar 08, 2024	8632517	Post IPO	9488083	7639613	1929029	4269182
Jan 19, 2024	2408908	Post IPO	5349066	8280748	3219172	8096430

Access funding benchmarks and valuations. Sign up today!

View details of Calidi Biotherapeutics's funding rounds and investors

The founders of Calidi Biotherapeutics is Megan Camaisa.

Here are the details of Calidi Biotherapeutics' key team members:

Megan Camaisa: Co-Founder of Calidi Biotherapeutics.
Contact Info: 1 email address

View details of Calidi Biotherapeutics's Founder profiles and Board Members

Calidi Biotherapeutics' employee count trend

Calidi Biotherapeutics has 32 employees as of Jul 26. Here is Calidi Biotherapeutics's employee count trend over the years:

Employee count trend for Calidi Biotherapeutics

Uncover Calidi Biotherapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Calidi Biotherapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Calidi Biotherapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
459th	Calidi Biotherapeutics 2018, San Diego (United States), Public	Developer of gene therapies for the treatment of cancer and other indications	-	CIRM, Jackson Investment Group & 2 others	53/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Calidi Biotherapeutics's competitors? Click here to see the top ones

Calidi Biotherapeutics has made no investments or acquisitions yet.

Here is the latest report on Calidi Biotherapeutics's sector:

Free

Oncology - Sector Report

Edition: July, 2026 (74 Pages)

View all reports related to Calidi Biotherapeutics

Media has covered Calidi Biotherapeutics for a total of 20 events in the last 1 year, 11 of them have been about company updates and 2 about partnerships.